Background: Schizophrenia patients and their parents have an increased risk of immune disorders compared to population controls and their parents. This may be explained by genetic overlap in the pathogenesis of both types of disorders. The purpose of this study was to investigate the genetic overlap between schizophrenia and three immune disorders and to compare with the overlap between schizophrenia and two disorders not primarily characterized by immune dysregulation: bipolar disorder and type 2 diabetes. Methods: We performed a polygenic risk score analysis using results from the schizophrenia Psychiatric GWAS consortium (PGC) (8922 cases and 9528 controls) and five Wellcome Trust Case Control Consortium (WTCCC) case samples as target cases: bipolar disorder (n = 1998), type 1 diabetes (n = 2000), Crohn's diseases (n = 2005), rheumatoid arthritis (n = 1999), and type 2 diabetes (n = 1999). The WTCCC British Birth Cohort and National Blood Service samples (n = 3004) were used as target controls. Additionally, we tested whether schizophrenia polygenic risk scores significantly differed between patients with immune disorder, bipolar disorder, and type 2 diabetes respectively. Results: Polygenic risk scores for schizophrenia significantly predicted disease status in all three immune disorder samples (Nagelkerke-R 2 1.1%-1.3%; p b 0.05). The polygenic risk of schizophrenia in patients with immune disorders was significantly lower than in patients with bipolar disorder (Nagelkerke-R 2 6.0%; p b 0.05), but higher than in type 2 diabetes patients (Nagelkerke-R 2 0.5%; p b 0.05).
Introduction
Schizophrenia is to a large extent influenced by genetic factors (Sullivan et al., 2003) . The genetic architecture is complex: between 23% and 50% of the variance is explained by thousands of independent common genetic variants (Lee et al., 2012; Ripke et al., 2013) , suggesting a polygenic model in which a large number of genetic variants contribute to disease risk (Purcell et al., 2009; Lee et al., 2012) . Epidemiological studies have shown increased incidence of immune disorders in patients with schizophrenia and their relatives. A large epidemiological study performed in Denmark, including 7704 patients with schizophrenia and 192,590 matched controls without a psychiatric record, showed that schizophrenia patients have a 45% higher lifetime incidence of one or more immune disorders which were present prior to the onset of schizophrenia compared to matched controls (Eaton et al., 2006) . This increased risk is not merely a consequence of the psychiatric disorder since the diagnosis of immune disorder was made before the onset of schizophrenia. Furthermore, the incidence rate ratio (IRR) was also higher in parents of schizophrenia patients than among parents of comparison subjects. The risk for 12 out of 29 reported immune disorders in parents of schizophrenia patients was significantly increased, whereas no significant decrease in risk was reported for any of the disorders (Eaton et al., 2006) .
The increased incidence of immune disorders in schizophrenia patients and their parents is generally consistent with other epidemiological findings (Leucht et al., 2007; Eaton et al., 2010; Chen et al., 2012) . A notable exception is the risk of rheumatoid arthritis, which has been found to be increased in parents of schizophrenia patients compared to parents of controls (Gilvarry et al., 1996; Eaton et al., 2006) , whereas other epidemiological studies comparing patients with controls have reported schizophrenia to be a protective factor for rheumatoid arthritis (Leucht et al., 2007; Chen et al., 2012) . This discrepancy suggests that although environmental and diseaserelated factors may protect schizophrenia patients from rheumatoid arthritis, genetic or other family-related factors may increase the risk of rheumatoid arthritis.
One of the hypotheses for the increased incidence of immune disorders in schizophrenia patients and their relatives is that common molecular pathways are involved in the pathogenesis of both types of disorders. Genetic alterations in these pathways may therefore contribute to a higher incidence of both schizophrenia and immune diseases. Obvious candidates for such shared genetic risk factors include the variants in the human leukocyte antigen (HLA) region which contribute to the risk of schizophrenia (Purcell et al., 2009; Stefansson et al., 2009) . In addition, a recent study showed that a relatively large segment at chromosome 5 is enriched for single nucleotide polymorphisms (SNPs) which are significantly associated with schizophrenia (Gladwin et al., 2012) . This region contains genes previously found to be related with schizophrenia (e.g., ACSL6, NEUROG1) and many immune-related genes, such as interleukin (IL)-4, IL-5, IL-13, and transforming growth factor (TGF) β-1. Interestingly, linkage studies had already implicated chromosome 5q31 in both schizophrenia and Crohn's disease (Schwab et al., 2000; Rioux et al., 2001) .
Thus far, the genetic overlap between schizophrenia and autoimmune disorders has been investigated by targeted approaches which focus on the role of specific candidate genes or regions which may contribute to the risk of both types of disorders. However, like schizophrenia, immune disorders have a complex genetic architecture (Goris and Liston, 2012; Parkes et al., 2013) . Therefore, a more systematic approach would be to study the genetic overlap between schizophrenia and immune disorders based on genome-wide association data using polygenic risk score analysis (Purcell et al., 2009) . Polygenic risk scores are a measure of disease liability and can be used to investigate the genetic overlap between disorders at a genomewide level.
The aim of this study is to investigate the genome-wide genetic overlap between schizophrenia and three disorders primarily characterized by immune dysregulation: type 1 diabetes, rheumatoid arthritis, and Crohn's disease. We compare the genetic overlap between schizophrenia and immune disorder patients with the overlap between schizophrenia and bipolar and type 2 diabetes patients, a psychiatric disease and a somatic disease which is not primarily characterized by immune dysfunction.
Methods

Data
We used results from the schizophrenia Psychiatric GWAS Consortium (PGC) data, a large collection of 17 case-control GWAS samples of European descent (9394 cases and 12,462 controls in total) (Ripke et al., 2011) , to compute polygenic risk scores in five casecontrol samples from the Wellcome Trust Case Control Consortium (WTCCC) (Burton et al., 2007) . The case samples included type 1 diabetes (T1D) (n = 2000), rheumatoid arthritis (RA) (n = 1999), Crohn's disease (CD) (n = 2005), bipolar disorder (BD) (n = 1998), and type 2 diabetes (BD) (n = 1999) (Burton et al., 2007) . These case samples were chosen to compare the three immune disorders (i.e., rheumatoid arthritis, Crohn's disease, and type 1 diabetes) with a psychiatric disease (bipolar disorder) and a somatic disorder which is not primarily characterized by immune dysfunction (type 2 diabetes). For all disorders the same WTCCC control subjects from the National Blood Service (NBS) (n = 1500) and 1958 Birth Cohort (1958BC) (n = 1504) were used (Burton et al., 2007) .
Quality control
We first removed subjects and SNPs that the WTCCC recommended to exclude (Burton et al., 2007) . See Fig. S1 in the Supplemental information for a detailed flow chart of the subsequent pre-imputation Filter 1 to 5. Before merging the WTCCC case and control samples, we applied the following filtering steps to the seven WTCCC subsamples using PLINK (Purcell et al., 2007) : minor allele frequency (b0.01), genotype missingness (N0.05), individual missingness (N0.02), genotype missingness once again (N 0.02) (Filter 1), Hardy-Weinberg equilibrium in controls (p b 0.001) (Filter 2), and minor allele frequency difference with a HapMap reference panel (N0.1) (Filter 3). The reference panel consisted of HapMap III founders from the CEPH Utah residents with Northern and Western European ancestry sample (CEU) and Tuscans in Italy (TSI) sample (n = 200) (Altshuler et al., 2010) .
After combining the NBS and 1958BC control samples, we removed SNPs significantly (p b 10
) associated with control sample membership (Filter 4). Subsequently, we combined case and control samples for each disorder, applied Filter 1 again to the resulting case-control samples, and removed any SNPs which were extremely significantly (p b 10 −50
) associated with disease status (Filter 5).
Principal component analysis
To correct for population stratification, we then calculated ten principal components for each WTCCC case-control sample. Each case-control sample was pruned to ensure relative independence between SNPs (PLINK command -indep-pairwise 50 5 0.2) for principal component analysis. The remaining SNPs were used to calculate ten principal components with EIGENSTRAT (Price et al., 2006) . We similarly computed ten principal components for all cases combined to allow for correction of population stratification in a direct comparison of diseases (see section).
Imputation
After principal component analysis, all WTCCC subsamples were imputed with Beagle (Browning and Browning, 2007) using the HapMap Phase III CEU + TSI founders (version 2, build 36) as a reference panel (Altshuler et al., 2010) . SNPs with a quality threshold of r 2 b 0.6 were excluded. The 113,664 independent SNPs remaining after the schizophrenia PGC clumping analysis were considered for upstream analysis (Ripke et al., 2011) . Further post-imputation QC consisted of removing SNPs with MAF b 0.01. Additionally, subjects identified as outliers (s.d. N 6) during principal component analysis were removed from the case-control samples. One of the members of a pair of relatives (pi-hat N 0.2 in PLINK) was removed as well. Table S1 in the Supplemental information shows the number of subjects and SNPs retained per case-control sample after these preprocessing steps.
Meta-analysis of PGC schizophrenia effect sizes
We meta-analyzed the effect sizes of the PGC schizophrenia samples (Ripke et al., 2011) using a fixed effects model in METAL (Willer et al., 2010) , excluding the Cardiff UK sample to prevent overlap with the WTCCC controls (resulting in 8922 cases and 9528 controls).
Polygenic risk score analysis
Based on the meta-analyzed log(odds ratios) we computed additive schizophrenia polygenic risk scores for individuals in all five preprocessed WTCCC case-control samples using PLINK (Purcell et al., 2007) . Based on different p-value thresholds for association with schizophrenia (p b 0.1 to p b 1 with steps of 0.1), we created different subsets of SNPs to compute the polygenic risk scores. These thresholddependent polygenic risk scores were then standardized and used as a predictor in logistic regression to predict disease status in each respective case-control sample. Standardization limits the range of the coefficients, but does not affect the Nagelkerke-R 2 and p-values. To account for differences in population structure, we first included only 10 PCA components as covariates in the logistic regression and then added the polygenic risk score in a second model. We used the difference in Nagelkerke's pseudo-R 2 between the two nested models to represent the effect of polygenic risk score above and beyond the effect of population stratification. The Nagelkerke R 2 is analogous, but not equal to the R 2 in linear regression. As chromosome six harbors the HLA region, we performed the polygenic risk score analysis with and without SNPs located on chromosome six to check whether genetic overlap was limited to SNPs on chromosome six or was distributed across the genome. Similar to Purcell et al. (2009) , for each analysis we reported the logistic regression coefficient of the risk prediction score with standard error and the difference in Nagelkerke-R 2 between the two nested models. To assess significance, the Nagelkerke's pseudo-R 2 was compared with a one-sided 95% confidence interval of an empirical null distribution. This null distribution was created by repeating the same analysis a 1000 times while randomly permuting disease status in the respective WTCCC case-control sample.
Comparison of disorders
We assessed whether bipolar disorder, immune disorders, and type 2 diabetes differ significantly in terms of genetic overlap with schizophrenia. For this analysis, we combined immune cases in one group and performed an overall comparison of the polygenic risk score in the three resulting case groups with an ANCOVA, correcting for population stratification (ten PCA components which were calculated in the combined case samples). To explore which groups were significantly different, we compared the risk score of immune cases with that of bipolar disorder cases and type 2 diabetes cases respectively, similarly correcting for population stratification.
Results
All diseases were positively associated with schizophrenia. In other words, a higher genetic risk for schizophrenia was associated with a higher genetic risk for each of the five disorders (see positive coefficients in Table 1 ). Fig. 1 shows the predictive power of the schizophrenia polygenic risk score, excluding chromosome six, which harbors the immune related HLA region. Different thresholds for p-values in the schizophrenia data were used; e.g., p threshold = 0.1 indicates that only those SNPs with a p-value below 0.1 in the schizophrenia data were included in the polygenic score analysis. Including more SNPs generally resulted in improved prediction. This implies that many small effect SNPs associated with schizophrenia are involved in all five disorders.
The extent to which the genetic liability for schizophrenia predicted disease status in another disorder varied. As expected, bipolar disorder was best predicted by schizophrenia polygenic risk score (maximum Nagelkerke-R 2 6.0%; p emp b 0.01; empirical p value based on 1000 permutations). The risk of three immune disorders type 1 diabetes, Crohn's disease, and rheumatoid arthritis was also significantly associated with the schizophrenia risk score (maximum Nagelkerke-R 2 ranged between 1.1%-1.3%; p emp b 0.01). It is worth noting that excluding or including chromosome six had a relatively minor impact on the results (maximum difference in Nagelkerke-R 2 = 0.2%). This indicates that the HLA region is not the major driving force behind the association between schizophrenia risk score and disease status in immune disorders. Finally, type 2 diabetes was least predicted by the genetic liability for schizophrenia (maximum Nagelkerke-R 2 0.5%; p emp b 0.01).
To assess whether the differences between bipolar disorder, immune disorders, and type 2 diabetes were significant, we combined type 1 diabetes, Crohn's disease, and rheumatoid arthritis in one group of immune cases. The mean schizophrenia polygenic risk scores in the three case groups (immune vs. bipolar disorder vs. type 2 diabetes) were significantly different (F(2, 7957) = 83.0; p b 0.05). Polygenic risk scores differed significantly between bipolar cases and immune cases (p b 0.05; based on SNPs with p threshold b 1) as well as between immune cases and type 2 diabetes cases (p b 0.05; based on SNPs with p threshold b 1) (see Table S2 in the Supplemental information for pairwise comparisons for all five disorders).
Discussion
To increase our understanding of the association between schizophrenia and immune disorders in epidemiological studies, we performed a polygenic risk score analysis in which a genetic risk score based on schizophrenia data predicted the risk of three immune disorders: type 1 diabetes, Crohn's disease, and rheumatoid arthritis. We report that the genetic liability for schizophrenia significantly predicts disease status of all three immune disorders. This implies that immune disorder patients show an increased genetic risk of schizophrenia compared to population controls.
The genetic overlap of schizophrenia with immune disorders is 1% (Nagelkerke-R 2 ), which is lower than the 6% overlap of schizophrenia with bipolar disorder. The relatively large genetic overlap between schizophrenia and bipolar disorder is consistent with earlier studies based on a variety of methods that have reported a genetic link between schizophrenia and bipolar disorder (Purcell et al., 2009; Huang et al., 2010; Lee et al., 2013; Smoller et al., 2013) . A similar analysis in 2009 on a smaller subset of the same data only found a genetic overlap between schizophrenia and bipolar disorder (Purcell et al., 2009) . In that study no significant genetic overlap was found between schizophrenia and respectively Crohn's disease, rheumatoid arthritis, type 1, and type 2 diabetes. The main difference between the present study ) of schizophrenia polygenic risk score for five diseases: bipolar disorder (BD), type-1 diabetes (T1D), Crohn's disease (CD), rheumatoid arthritis (RA), and type-2 diabetes (T2D). Different bars represent p-value thresholds for the SNPs used in the analysis. SNPs located at chromosome six are excluded. Horizontal black lines identify an empirical 5% significance threshold based on 1000 random permutations of case-control labels in the validation sample. p-Value of differences between disorders is based on a pairwise comparison of polygenic risk scores in respective cases corrected for 10 PCA components and p threshold b 1. and the original study is the schizophrenia sample size used to estimate SNP effect sizes (8922 cases and 9528 controls vs 3322 cases and 3587 controls). In polygenic risk score analysis larger discovery sample sizes improve the SNP effect size estimates, increasing power to detect genetic overlap. For example, larger discovery sample sizes increased the explained variance in schizophrenia test samples from 3% to 6% (Purcell et al., 2009; Ripke et al., 2013) . Hence, the significant associations in the present study can be explained by the larger sample size of the schizophrenia PGC data. This illustrates the value of replicating a previous polygenic risk score analysis on a larger dataset.
Interestingly, the overlap between schizophrenia and immune disorders was larger than the overlap of 0.5% between schizophrenia and type 2 diabetes, which is not primarily characterized by immune dysregulation. This also points towards the involvement of genetic factors related to immune processes in schizophrenia, although we cannot rule out the reverse; that brain processes causing schizophrenia are involved in immune disorders. The small, but significant, genetic overlap between schizophrenia and type 2 diabetes may seem surprising at first. However, there is recent evidence that schizophrenia and type 2 diabetes are indeed genetically related. For example, relatives from patients with a non-affective psychotic disorder have an increased risk for diabetes (van Welie et al., 2013) . In that study it was unknown whether relatives were diagnosed with type 1 vs. type 2 diabetes, but provided the larger prevalence of type 2 diabetes in adults, the majority of the diabetes cases can be assumed to have type 2 diabetes. Also, common immune-related pathways between schizophrenia and type 2 diabetes have been reported in a pathway analysis . Finally, immuno-therapy can normalize insulin resistance in type 2 diabetes patients, suggesting an important role of the immune system in type 2 diabetes as well (Winer et al., 2009) . Summarizing, our results support the hypothesized genetic overlap between schizophrenia and immune processes, but future studies should explore the mechanisms which explain the small genetic overlap between schizophrenia and type 2 diabetes.
Our analysis excluded chromosome six with the HLA region , showing that this region only partly contributes to the genetic overlap between schizophrenia and immune disorders (a decrease in Nagelkerke R 2 b 0.22% after removal of chromosome six). It is not surprising that the genetic overlap is not restricted to the HLA region, since both schizophrenia and immune disorders have a complex genetic architecture (Lees et al., 2011; Lee et al., 2012; Stahl et al., 2012) . In genome-wide association studies of immune disorders, significantly associated loci are not only found in the HLA region, but are also located on many different chromosomes (Franke et al., 2010; Stahl et al., 2010; Bradfield et al., 2011) . Our study suggests that it is the genome-wide accumulation of shared loci with small effects which drives the genetic overlap between schizophrenia and immune disorders. While our results suggest that a genetic liability for schizophrenia increases the risk of rheumatoid arthritis, schizophrenia has been repeatedly reported as a potent protective factor for rheumatoid arthritis (e.g. Chen et al., 2012; see Leucht et al., 2007 for a recent overview). This is not necessarily inconsistent, since medication or other life style changes in schizophrenia patients may decrease the risk of rheumatoid arthritis (Laan et al., 2009; Kato et al., 2011) , while genetic and shared environmental factors could still increase the risk of arthritis. This is illustrated by Eaton and colleagues who showed that incidence of rheumatoid arthritis in parents of schizophrenia patients is larger than in parents of matched population controls (Eaton et al., 2006) .
In conclusion, our results contribute to an accumulating and converging body of evidence that immunological factors play a role in the etiology of schizophrenia (Eaton et al., 2006 (Eaton et al., , 2010 Müller and Schwarz, 2010; Chen et al., 2012; Sainz et al., 2012; Gardiner et al., 2013; Horváth and Mirnics, 2014) . Despite the increased interest in the role of immune dysregulation in schizophrenia, many questions remain. For example, our results do not rule out the possibility that the genetic overlap between schizophrenia and immune disorders mostly involves brain processes instead of immune processes. To clarify the role of immune dysregulation in schizophrenia, it is necessary to identify which biological pathways are implicated in both schizophrenia and immune disorders. A less ambitious but nonetheless important goal is to determine whether immunological components can also be identified in other neuropsychiatric disorders. These unanswered questions combined with the reported findings of the last few years make the role of immune dysregulation in neuropsychiatric disorders a promising and exciting area of research for the foreseeable future.
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